Akeso, Inc. (HKG:9926)
88.60
-0.50 (-0.56%)
Nov 11, 2026, 4:08 PM HKT
Akeso Revenue
Akeso had revenue of 1.81B CNY in the half year ending June 30, 2026, with 76.21% growth. This brings the company's total for the last twelve months to 3.45B, up 37.43% year-over-year. In the year 2025, Akeso had annual revenue of 3.06B with 43.90% growth. That makes Akeso the 11,196th largest company in the world by revenue and 672nd in Hong Kong.
Revenue (ttm)
3.45B CNY
Revenue Growth
+37.43%
P/S Ratio
20.67
Revenue / Employee
845.28K CNY
Employees
4,082
Market Cap
83.39B HKD
Revenue by Geography
- Mainland China 2.70B 88.4%
- United States of America (USA) 338.52M 11.1%
- Other Regions 17.50M 0.6%
Fiscal year ended Dec 31, 2025 See the full Akeso breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.06B | 932.33M | 43.90% |
| Dec 31, 2024 | 2.12B | -2.40B | -53.08% |
| Dec 31, 2023 | 4.53B | 3.69B | 440.35% |
| Dec 31, 2022 | 837.66M | 612.03M | 271.26% |
| Dec 31, 2021 | 225.63M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sino Biopharmaceutical | 38.91B |
| WuXi Biologics | 27.27B |
| 3SBio | 20.63B |
| Innovent Biologics | 18.13B |
| RemeGen | 9.70B |
| Shanghai Henlius Biotech | 8.58B |
| Genscript Biotech | 6.63B |
| InnoCare Pharma | 3.93B |
Akeso News
- 5 days ago - Phase II Study of Ivonescimab in the Perioperative Setting for Resectable NSCLC Published in Nature Medicine - PRNewsWire
- 5 days ago - Akeso's Ivonescimab Received Priority Review In China For Biliary Tract Cancer - Nasdaq
- 6 days ago - Ivonescimab Receives NMPA Priority Review for First-Line Biliary Tract Cancer - PRNewsWire
- 16 days ago - Akeso announces Phase III HARMONi-GI1 trial met its primary endpoint - TheFly
- 16 days ago - Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented at the ESMO 2026 Presidential Symposium - PRNewsWire
- 22 days ago - Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab - PRNewsWire
- 4 weeks ago - Akeso Doses First Patient In Phase 3 Cadonilimab Study For MSI-H Colon Cancer - Nasdaq
- 4 weeks ago - Akeso announces first patient dosed in Phase III study of cadonilimab - TheFly